-
Stay Connected
Get the latest news on exciting speakers, workshops & learning opportunities at ISDE 2021.
Subscribe for Updates
Esophageal cancer remains a major global health problem, with outcomes shaped by tumor biology, stage, location, and access to specialist care. The disease is broadly divided into squamous cell carcinoma and adenocarcinoma, two subtypes that can respond differently to systemic treatment.
Immunotherapy has changed the treatment landscape by helping the immune system recognize and attack malignant cells. Checkpoint inhibitors are now part of care for selected patients, particularly those with advanced disease, specific biomarker profiles, or tumors treated with combined chemotherapy.
The evidence continues to evolve rapidly. Research presented through specialist forums such as the ISDE 2021 congress has helped place new clinical trial findings within the wider context of surgery, radiotherapy, pathology, and multidisciplinary esophageal care.
The immune system can identify abnormal cells, but cancer may suppress this response through inhibitory pathways. The PD-1 receptor on T cells and its ligand, PD-L1, form one important immune checkpoint. Drugs that block this interaction can restore T-cell activity against tumor cells.
Nivolumab, pembrolizumab, and other checkpoint inhibitors have been studied in advanced esophageal and gastroesophageal junction cancers. Their benefit is usually measured through overall survival, progression-free survival, tumor response, and duration of response. Clinical decisions must also account for toxicity, previous treatment, performance status, and patient preference.
Trials have shown that immunotherapy can improve outcomes for selected people with unresectable or metastatic disease. Benefit is often greater in tumors with higher PD-L1 expression, although PD-L1 testing is not a perfect predictor. Different studies use distinct scoring systems, including tumor proportion score and combined positive score, so results must be interpreted in their clinical context.
Combination treatment is another important development. Chemotherapy may release tumor antigens and alter the tumor microenvironment, potentially making cancer more visible to immune cells. In several treatment settings, an immune checkpoint inhibitor combined with platinum-based chemotherapy has become an option for eligible patients.
Biomarker testing supports a more individualized approach. PD-L1 expression is commonly assessed, while mismatch repair deficiency and microsatellite instability can identify tumors that are especially sensitive to immune checkpoint blockade. Human epidermal growth factor receptor 2 status may also influence the use of targeted therapy in adenocarcinoma.
Other markers under investigation include tumor mutational burden, gene-expression signatures, immune-cell infiltration, and circulating tumor DNA. None can yet predict benefit with complete accuracy. A low biomarker score does not always exclude benefit, while a high score does not guarantee a meaningful response.
| Treatment setting | Common immunotherapy approach | Main clinical consideration |
|---|---|---|
| Metastatic disease | Checkpoint inhibitor alone or with chemotherapy | Histology, PD-L1 score, fitness, and prior treatment |
| Locally advanced disease | Immunotherapy after chemoradiation and surgery in selected cases | Pathologic response and residual disease |
| HER2-positive adenocarcinoma | Immunotherapy with chemotherapy, sometimes alongside HER2-directed treatment | HER2 status and regimen eligibility |
| MSI-high or mismatch repair-deficient disease | Checkpoint blockade may be particularly effective | Confirm the molecular result |
| Clinical trial setting | Novel combinations, vaccines, or cellular therapies | Access, protocol requirements, and close monitoring |
The role of immunotherapy is expanding beyond metastatic cancer. In locally advanced disease, treatment may include chemotherapy, radiation, surgery, and postoperative systemic therapy. Evidence supports adjuvant nivolumab for some patients with residual pathological disease after neoadjuvant chemoradiation and resection, reducing the risk of recurrence in appropriately selected cases.
Perioperative strategies are also being evaluated. Giving immunotherapy before surgery may stimulate a stronger immune response while the tumor and its antigens remain present. Postoperative treatment may then target microscopic residual disease. These approaches require careful coordination because surgery, nutritional status, wound healing, and immune-related adverse events can affect treatment timing.
Checkpoint inhibitors have a different safety profile from conventional chemotherapy. Immune activation may cause inflammation in healthy organs, producing dermatitis, colitis, hepatitis, pneumonitis, thyroid dysfunction, adrenal insufficiency, or less common neurological and cardiac complications.
Early recognition is essential. New diarrhea, breathlessness, jaundice, severe fatigue, rash, or changes in blood tests should be assessed promptly. Depending on severity, treatment may involve holding immunotherapy, administering corticosteroids, involving a specialist, or using additional immunosuppression. Patients should receive clear education before treatment begins and should keep all follow-up appointments.
Future progress will depend on matching the right treatment to the right tumor at the right time. Researchers are studying dual checkpoint blockade, immunotherapy with radiotherapy, antibody-drug conjugates, cancer vaccines, bispecific antibodies, and adoptive cell therapies. The tumor microenvironment is also a major focus because suppressive immune cells and abnormal blood vessels can limit treatment activity.
Clinical trials are increasingly examining combinations designed to overcome primary resistance and acquired resistance. Better use of molecular profiling, serial blood testing, and artificial intelligence-assisted pathology may refine response prediction. Patients seeking congress resources can review registration information from the ISDE 2021 archive to understand how specialist educational programs connect emerging evidence with clinical practice.
Immunotherapy is now an established component of esophageal cancer treatment, yet its greatest potential remains ahead. Continued research, careful biomarker interpretation, and coordinated patient care can turn promising trial results into safer and more durable outcomes. Review current evidence with a qualified oncology team and use specialist educational resources to support informed treatment decisions.